DK172103B1 - Hidtil ukendte 3,3-difenylpropylaminer, farmaceutiske præparater indeholdende disse, deres anvendelse til fremstilling af et anticholinergt lægemiddel samt fremgangsmåde til deres fremstilling - Google Patents

Hidtil ukendte 3,3-difenylpropylaminer, farmaceutiske præparater indeholdende disse, deres anvendelse til fremstilling af et anticholinergt lægemiddel samt fremgangsmåde til deres fremstilling Download PDF

Info

Publication number
DK172103B1
DK172103B1 DK172590A DK172590A DK172103B1 DK 172103 B1 DK172103 B1 DK 172103B1 DK 172590 A DK172590 A DK 172590A DK 172590 A DK172590 A DK 172590A DK 172103 B1 DK172103 B1 DK 172103B1
Authority
DK
Denmark
Prior art keywords
methyl
yield
found
phenylpropylamine
hydroxy
Prior art date
Application number
DK172590A
Other languages
Danish (da)
English (en)
Other versions
DK172590D0 (da
DK172590A (da
Inventor
Nils Aake Joensson
Bengt Aake Sparf
Lembit Mikiver
Pinchas Moses
Lisbet Nilvebrant
Gunilla Glas
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20371146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK172103(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Publication of DK172590D0 publication Critical patent/DK172590D0/da
Publication of DK172590A publication Critical patent/DK172590A/da
Application granted granted Critical
Publication of DK172103B1 publication Critical patent/DK172103B1/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63Esters of sulfonic acids
    • C07C309/72Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/20Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/56Ring systems containing bridged rings
    • C07C2603/58Ring systems containing bridged rings containing three rings
    • C07C2603/70Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DK172590A 1988-01-22 1990-07-19 Hidtil ukendte 3,3-difenylpropylaminer, farmaceutiske præparater indeholdende disse, deres anvendelse til fremstilling af et anticholinergt lægemiddel samt fremgangsmåde til deres fremstilling DK172103B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE8800207A SE8800207D0 (sv) 1988-01-22 1988-01-22 Nya aminer, deras anvendning och framstellning
SE8800207 1988-04-25
PCT/SE1989/000016 WO1989006644A1 (en) 1988-01-22 1989-01-20 New amines, their use and preparation
SE8900016 1989-01-20

Publications (3)

Publication Number Publication Date
DK172590D0 DK172590D0 (da) 1990-07-19
DK172590A DK172590A (da) 1990-07-19
DK172103B1 true DK172103B1 (da) 1997-10-27

Family

ID=20371146

Family Applications (1)

Application Number Title Priority Date Filing Date
DK172590A DK172103B1 (da) 1988-01-22 1990-07-19 Hidtil ukendte 3,3-difenylpropylaminer, farmaceutiske præparater indeholdende disse, deres anvendelse til fremstilling af et anticholinergt lægemiddel samt fremgangsmåde til deres fremstilling

Country Status (17)

Country Link
EP (2) EP0354234A1 (xx)
JP (1) JP2664503B2 (xx)
AT (1) ATE65990T1 (xx)
AU (1) AU635493B2 (xx)
CA (1) CA1340223C (xx)
DE (2) DE68900180D1 (xx)
DK (1) DK172103B1 (xx)
ES (1) ES2029384T4 (xx)
FI (1) FI109900B (xx)
GR (1) GR3002854T3 (xx)
HK (1) HK64494A (xx)
HU (2) HU212729B (xx)
LU (1) LU90259I2 (xx)
NL (1) NL980020I2 (xx)
NO (2) NO173496C (xx)
SE (1) SE8800207D0 (xx)
WO (1) WO1989006644A1 (xx)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
ZA969363B (en) * 1995-11-08 1997-11-18 Smithkline Beecham Corp An improved process for preparing aromatic ring-fused cyclopentane derivatives.
AU728395B2 (en) 1996-07-19 2001-01-11 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
KR20000057548A (ko) * 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
SE9701144D0 (sv) * 1997-03-27 1997-03-27 Pharmacia & Upjohn Ab Novel compounds, their use and preparation
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
NZ504618A (en) 1998-08-27 2002-09-27 Pharmacia & Upjohn Ab Controlled release therapeutic formulation for administering tolterodine maintaining a constant serum level
DE29923134U1 (de) * 1999-11-16 2000-06-29 Sanol Arznei Schwarz Gmbh Stabile Salze neuartiger Derviate von 3,3-Diphenylpropylaminen
US6566537B2 (en) 1999-12-30 2003-05-20 Pharmacia Ab Process and intermediates
SE9904850D0 (sv) * 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
DE10028443C1 (de) * 2000-06-14 2002-05-29 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen, (R,S)- und (R)-4-Phenyl-2-chromanon-6-carbonsäure sowie (R)-4-Phenyl-2-chromanon-carbonsäure-cinchonidinsalz und deren Verwendung zur Herstellung eines rechtsdrehenden Hydroxybenzylalkohols und von pharmazeutischen Zusammensetzungen
DE10033016A1 (de) * 2000-07-07 2002-01-24 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen
CA2464217A1 (en) * 2001-11-05 2003-05-15 Pharmacia & Upjohn Company Antimuscarinic aerosol
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
MXPA05000434A (es) 2002-07-08 2005-04-19 Ranbaxy Lab Ltd Derivados de hexano [3.1.0] azabiciclo 3,6-disustituido utiles como antagonistas de receptor muscarinico.
WO2004014853A1 (en) 2002-07-31 2004-02-19 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
EP1545508A4 (en) * 2002-08-09 2009-11-25 Ranbaxy Lab Ltd 3,6-DISUBSTITUTED AZABICYCLO ¬3.1.0 HEXANE DERIVATIVES AS USEFUL AS MUSCARINIC RECEPTOR AGONISTS
EP1534675B1 (en) 2002-08-23 2009-02-25 Ranbaxy Laboratories, Ltd. Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo¬3.1.0 hexane derivatives as muscarinic receptor antagonists
EP1572648B1 (en) 2002-12-10 2008-07-09 Ranbaxy Laboratories, Ltd. 3,6-disubstituted azabicyclo (3.1.0)-hexane derivatives as muscarinic receptor antagonists
RU2331438C2 (ru) 2002-12-13 2008-08-20 Уорнер-Ламберт Компани Ллс Альфа-2-дельта лиганд для лечения симптомов нижних мочевыводящих путей
AU2002347552A1 (en) 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
ATE386738T1 (de) 2002-12-23 2008-03-15 Ranbaxy Lab Ltd Flavaxat-derivate als muscarin-rezeptor antagonisten
AU2004206110A1 (en) 2003-01-22 2004-08-05 Pfizer Health Ab Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004078700A1 (en) * 2003-03-06 2004-09-16 Ranbaxy Laboratories Limited 3,3-diarylpropylamine derivatives and processes for isolation thereof
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
US7393874B2 (en) 2003-04-08 2008-07-01 Hetero Drugs Limited Polymorphs of tolterodine tartrate
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
ATE362364T1 (de) 2003-04-10 2007-06-15 Ranbaxy Lab Ltd Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten
WO2004089899A1 (en) 2003-04-10 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
CN100436414C (zh) 2003-04-11 2008-11-26 兰贝克赛实验室有限公司 作为毒蕈碱受体拮抗剂的氮杂双环衍生物
MXPA05011509A (es) 2003-04-25 2005-12-15 Pharmacia & Upjohn Co Llc 3,3-difenilpropilaminas (tolterodina) sustituidas con halogenos que presentan actividad antimuscarinica.
CA2522888C (en) * 2003-05-23 2012-07-17 Bridge Pharma, Inc. Smooth muscle spasmolytic agents
ES2235648B1 (es) * 2003-12-22 2006-11-01 Ragactives, S.L. Procedimiento para la obtencion de tolterodina.
CA2551501C (en) * 2003-12-24 2012-05-29 Cipla Limited Tolterodine, compositions and uses thereof, and preparation of the same
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
JP4513535B2 (ja) * 2004-12-03 2010-07-28 住友化学株式会社 トルテロジンの製造方法
WO2006066931A1 (en) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Process for preparation of 3-(2-hydroxy-5-methylphenyl)-n,n-diisopropyl-3­phenylpropylamine
ITMI20050249A1 (it) 2005-02-18 2006-08-19 Dipharma Spa Procedimento per la preparazione di tolterodina
WO2007039918A1 (en) * 2005-10-06 2007-04-12 Natco Pharma Limited Novel process for the preparation of tolterodine
CA2626612A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
RU2008120332A (ru) * 2005-12-20 2010-01-27 Пфайзер Продактс Инк. (Us) Фармацевтическая композиция для лечения luts, содержащая ингибитор pde5 и мускариновый антагонист
ITMI20060110A1 (it) * 2006-01-24 2007-07-25 Dipharma Spa Procedimento per la purificazione di tolterodina
EP1999107A2 (en) 2006-03-20 2008-12-10 Pfizer Limited Amine derivatives
MX2008015973A (es) 2006-06-12 2009-01-12 Sanol Arznei Schwarz Gmbh Intermediario quiralico nuevo, proceso para producir el mismo y su uso en la fabricacion de tolterodina, fesoterodina o el metabolito activo de los mismos.
BRPI0713314A2 (pt) 2006-06-20 2012-03-06 Lek Pharmaceuticals D.D. Processo para a preparação de 3-(2-hidróxi-5-fenil substituído)-n-alquil-3-fenilpropilaminas
WO2008017278A2 (en) * 2006-08-09 2008-02-14 Zentiva, A.S. Crystalline tolterodine tartarate and a pharmaceutical composition containing the same
CZ302585B6 (cs) * 2007-02-26 2011-07-20 Zentiva, A. S. Krystalická sul 2-[(1R)-3-[bis(1-methylethyl)amino]-1-fenylpropyl]-4-methylfenolu s kyselinou (2R,3R)-2,3-dihydroxybutandiovou
ITMI20082055A1 (it) * 2008-11-19 2009-02-18 Dipharma Francis Srl Procedimento per la preparazione di (r)-tolterodina base libera
MX2011011937A (es) * 2009-05-11 2012-01-27 Ratiopharm Gmbh Desfesoterodina en la forma de una sal del acido tartarico.
IL210279A0 (en) 2009-12-25 2011-03-31 Dexcel Pharma Technologies Ltd Extended release compositions for high solubility, high permeability acdtive pharmaceutical ingredients
EP2364966A1 (en) 2010-03-09 2011-09-14 LEK Pharmaceuticals d.d. Process for preparation of 3-(2-hydroxy-5-substituted phenyl)-3-phenylpropylamines, intermediates for making hydroxytolterodine
CN102329244A (zh) * 2010-07-13 2012-01-25 凯瑞斯德生化(苏州)有限公司 一种rs-托特罗定的制备方法及中间体化合物
ITMI20110410A1 (it) * 2011-03-15 2012-09-16 Cambrex Profarmaco Milano Srl Procedimento per la preparazione di (r)-tolterodina l-tartrato di forma cristallina definita
ITMI20121232A1 (it) 2012-07-16 2014-01-17 Cambrex Profarmaco Milano Srl Procedimento per la preparazione di 2-(3-n,n-diisopropilamino-1-fenilpropil)-4-idrossimetil-fenolo e suoi derivati
CN110372571B (zh) 2018-04-12 2022-11-15 中国科学院大连化学物理研究所 一种2-(2,2-二芳基乙基)-环胺衍生物或盐及合成和应用与组合物
WO2022256480A1 (en) * 2021-06-03 2022-12-08 Conagen Inc. Arylcoumarin synthesis with azeotropic removal of water

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK111894A (xx) * 1962-11-15
GB1169945A (en) * 1966-08-25 1969-11-05 Geistlich Soehne Ag Pharmaceutical Compositions containing Diphenylalkyl-amine Derivatives
GB1169944A (en) * 1966-08-25 1969-11-05 Geistlich Soehne Ag Novel 3,3-Diphenylpropylamines and processes for the preparation thereof

Also Published As

Publication number Publication date
GR3002854T3 (en) 1993-01-25
DK172590D0 (da) 1990-07-19
EP0354234A1 (en) 1990-02-14
DK172590A (da) 1990-07-19
AU2932989A (en) 1989-08-11
NO173496B (no) 1993-09-13
HK64494A (en) 1994-07-15
LU90259I2 (fr) 1998-09-16
NO1998023I1 (no) 1998-10-20
NO903085L (no) 1990-07-11
DE19875024I2 (de) 2002-09-26
AU635493B2 (en) 1993-03-25
NO173496C (no) 1993-12-22
EP0325571A1 (en) 1989-07-26
SE8800207D0 (sv) 1988-01-22
CA1340223C (en) 1998-12-15
ES2029384T3 (es) 1992-08-01
HU891069D0 (en) 1991-11-28
FI903688A0 (fi) 1990-07-20
DE68900180D1 (de) 1991-09-12
NL980020I1 (nl) 1998-09-01
JP2664503B2 (ja) 1997-10-15
WO1989006644A1 (en) 1989-07-27
FI109900B (fi) 2002-10-31
HU212729B (en) 1996-10-28
NO903085D0 (no) 1990-07-11
EP0325571B1 (en) 1991-08-07
NL980020I2 (nl) 1999-02-01
ES2029384T4 (es) 2011-05-30
HU210603A9 (en) 1995-05-29
ATE65990T1 (de) 1991-08-15
JPH03503163A (ja) 1991-07-18
HUT58040A (en) 1992-01-28

Similar Documents

Publication Publication Date Title
DK172103B1 (da) Hidtil ukendte 3,3-difenylpropylaminer, farmaceutiske præparater indeholdende disse, deres anvendelse til fremstilling af et anticholinergt lægemiddel samt fremgangsmåde til deres fremstilling
US5382600A (en) 3,3-diphenylpropylamines and pharmaceutical compositions thereof
ES2218924T3 (es) Compuestos de dimetil-(3-aril-but-3-enil)-amina como principio activo farmaceutico.
JPH0819065B2 (ja) ベンゾ融合シクロアルカンおよびオキサ‐およびチア‐シクロアルカントランス‐1,2‐ジアミン誘導体
NZ205269A (en) 4-(3-trifludromethylphenyl)-1,2,3,6-tetrahydro-pyridine derivatives and pharmaceutical compositions
CZ284256B6 (cs) Nový způsob výroby formoterolu a příbuzných sloučenin
US4426386A (en) Substituted phenyl piperidines
AU4991999A (en) Methods and compounds for treating depression and other disorders
FI78459C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara dialkylaminoalkoxibensylalkohol-derivat.
EP0057870A1 (en) N-optionelly substituted-2-amino-alpha-phenylphenethylamines and a method for their preparation
NZ196086A (en) 1-phenyl-2-cyclohexene-1-alkylamine derivatives and pharmaceutical compositions
FI94240B (fi) Menetelmä terapeuttisesti käyttökelpoisten 4-aryyli-4-piperidiinikarbinolien valmistamiseksi
EP0106486A2 (en) Improvements in or relating to novel octahydrobenz(f)isoquinolines
HU177798B (en) Process for producing substituted pyrrolydines
JPH05255302A (ja) 新規なクロマニルオキシアルキルアミン誘導体
EP0076669A1 (en) Novel 3-phenyl-1-indanamines, pharmaceutical compositions and methods of preparation
EP0034647B1 (en) 4-aryloxy-3-phenylpiperidine derivatives, intermediates, a process for the preparation of such compounds and their use as medicaments
KR910003711B1 (ko) 2-(n-피롤리디노)-3-이소부톡시-n-치환된 페닐-n-벤질-프로필아민의 제조방법
US5109006A (en) Certain pharmaceutically active 6H-imidazo[1,2-a]pyridine-5-ones
US6770636B2 (en) Phenyl-and phenylalkyl-substituted ethanolamines and ethylenediamines
EP0097628B1 (en) Piperidine derivatives, processes for their preparation and pharmaceutical preparation containing them
CA2417361C (en) New phenyl- and phenylalkyl-substituted ethanolamines and ethylenediamines
CS239947B2 (en) Processing of new benzazepin derivatives
US4937346A (en) Phenyl-azacykloalkanes
CA2573754C (en) Substituted amino compounds as 5-ht/na uptake inhibitors

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
B1 Patent granted (law 1993)
CTFF Application for supplementary protection certificate (spc) filed

Free format text: CA 1998 00018, 19980611, EXPIRES: 20120905

PBP Patent lapsed
PUP Patent expired